Sung Goo Yoon

Prof. Sung Goo Yoon

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Investigative and Clinical Urology
Verified
Journal Article
Open access
SKSeung Bin Kim
Seung Bin Kim
SYSung Goo Yoon
Sung Goo Yoon
JTJonghyun Tae
Jonghyun Tae
JKJae Yoon Kim
Jae Yoon Kim
JSJi Sung Shim
Ji Sung Shim
SKSeok Ho Kang
Seok Ho Kang
Kim SB, et al. Investig Clin Urol. 2018 Mar;59(2):98-105. https://doi.org/10.4111/icu.2018.59.2.98

1 January 2015 in Korean Journal of Urology
Verified
Journal Article
Open access
PDF file
JSJi Sung Shim
Ji Sung Shim
HCHoon Choi
Hoon Choi
TNTae Il Noh
Tae Il Noh
JTJong Hyun Tae
Jong Hyun Tae
SYSung Goo Yoon
Sung Goo Yoon
JPJae Young Park
Jae Young Park
Shim JS, et al. Korean J Urol. 2015 Jun;56(6):429-434. http://dx.doi.org/10.4111/kju.2015.56.6.429

1 January 2024 in Investigative and Clinical Urology
Verified
Journal Article
Open access
PDF file
CHChang Wan Hyun
Chang Wan Hyun
JHJae Young Hwang
Jae Young Hwang
SYSeong Woo Yun
Seong Woo Yun
TPTae Young Park
Tae Young Park
SYSung Goo Yoon
Sung Goo Yoon
JISUNG SHIMJISUNG SHIM
JISUNG SHIM
Hyun CW, et al. Investig Clin Urol. 2024 Mar;65(2):165-172. https://doi.org/10.4111/icu.20230272

9 March 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
SPSungwook Park
Sungwook Park
HKHeeseok Kang
Heeseok Kang
YCYukyoung Choi
Yukyoung Choi
SYSung Goo Yoon
Sung Goo Yoon
HPHyung Joon Park
Hyung Joon Park
KLKwan Hyi Lee
Kwan Hyi Lee
Bladder cancer, when diagnosed at an advanced stage, often necessitates inevitable invasive intervention. Consequently, non-invasive biosensor-based cancer detection and AI-based precision screening are being actively employed. However, the misclassification of cancer patients as normal-referred to as false negatives-remains a significant concern, as it could lead to fatal outcomes in lifespan. Moreover, while ensemble techniques such as soft voting and other methods can improve model accuracy and reduce misclassification, their effectiveness is limited and not applicable to all diagnostic tasks. Here, we developed a double stage cancer screening system that utilizes a sensitive urinary electrical biosensor implemented with an AI model and XAI interpretation tools. This system is designed for screening bladder cancer, well-known for its notable recurrence and high tendency to advance from non-invasive muscle tumors to muscle-invasive tumors. Four urinary biomarkers (CK8, CK18, PD-1, PD-L1) were measured by a field-effect transistor biosensor, and along with gender and age information, patients underwent initial screening by the CatBoost classification model. Patients initially classified as normal were reclassified using local explanations from neural networks offering a different perspective than CatBoost. After the second-stage screening, all of the false negatives from the initial screening could be correctly reclassified as cancer patients. Furthermore, global explanation guides the improvement of the AI model to be trained on an appropriate set of biomarker features to achieve high accuracy.


10 April 2025 in Journal of the Korean Medical Association
Verified
Journal Article
Open access
PDF file
SYSung Goo Yoon
Sung Goo Yoon
SKSeok Ho Kang
Seok Ho Kang
Purpose: Metastatic bladder cancer has historically been treated with platinum-based chemotherapy as the standard firstline therapy. Since the introduction of cisplatin-based regimens, advancements in treatment strategies have been limited. However, the recent emergence of immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) has significantly transformed the treatment landscape. Notably, the combination of enfortumab vedotin (EV) and pembrolizumab has demonstrated considerable clinical benefits, challenging traditional chemotherapy. This review aims to provide an overview of recent advancements in the treatment of metastatic bladder cancer.Current Concepts: Recent phase III clinical trials, notably EV-302/KEYNOTE-A39 and CheckMate 901, have reshaped the first-line management. EV combined with pembrolizumab has shown superior progression-free survival and overall survival compared to platinum-based chemotherapy, establishing it as a new standard of care. Patients ineligible for this regimen due to underlying comorbidities or toxicity may still benefit from alternative options. Such alternatives include platinum-based chemotherapy with ICI maintenance therapy, including avelumab or nivolumab. The selection of treatments should be individualized, taking into account specific patient factors, particularly platinum eligibility, renal function, and performance status.Discussion and Conclusion: The incorporation of ICIs and ADCs into the therapeutic landscape for metastatic bladder cancer has significantly improved patient outcomes. EV plus pembrolizumab has demonstrated substantial survival benefits, establishing it as a preferred first-line regimen for eligible patients. However, not all patients are candidates for this combination, emphasizing the necessity of individualized treatment strategies. Future research should focus on managing treatment-related adverse events and developing personalized therapies to maximizing efficacy while minimizing toxicity.